-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KITE-718 in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KITE-718 in Refractory Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KITE-718 in Refractory Acute Myeloid Leukemia Drug Details: KITE-718...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ruxolitinib Phosphate in Hidradenitis Suppurativa
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ruxolitinib Phosphate in Hidradenitis Suppurativa report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ruxolitinib Phosphate in Hidradenitis Suppurativa Drug Details: Ruxolitinib (INCB18424, Jakafi, Jakavi)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fosciclopirox in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fosciclopirox in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Fosciclopirox in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KITE-363 in Primary Mediastinal B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KITE-363 in Primary Mediastinal B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KITE-363 in Primary Mediastinal B-Cell Lymphoma Drug Details: KITE-363 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KITE-363 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KITE-363 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KITE-363 in Diffuse Large B-Cell Lymphoma Drug Details: KITE-363 is...
-
Product Insights
Pediatric Diffuse Intrinsic Pontine Glioma – Drugs In Development, 2023
Global Markets Direct’s, ‘Pediatric Diffuse Intrinsic Pontine Glioma - Drugs In Development, 2023’, provides an overview of the Pediatric Diffuse Intrinsic Pontine Glioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pediatric Diffuse Intrinsic Pontine Glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Pontine Glioma – Drugs In Development, 2023
Global Markets Direct’s, ‘Pontine Glioma - Drugs In Development, 2023’, provides an overview of the Pontine Glioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pontine Glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Medullary Thyroid Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Medullary Thyroid Cancer - Drugs In Development, 2023’, provides an overview of the Medullary Thyroid Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Medullary Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) – Drugs In Development, 2023
Global Markets Direct’s, ‘Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) - Drugs In Development, 2023’, provides an overview of the Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers...
-
Product Insights
Recurrent Glioblastoma Multiforme (GBM) – Drugs In Development, 2023
Global Markets Direct’s, ‘Recurrent Glioblastoma Multiforme (GBM) - Drugs In Development, 2023’, provides an overview of the Recurrent Glioblastoma Multiforme (GBM) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Recurrent Glioblastoma Multiforme (GBM), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...